Genomic Health Inc. (NASDAQ:GHDX)’s share price traded up 1.2% during trading on Wednesday . The stock traded as high as $26.49 and last traded at $26.47, with a volume of 55,111 shares changing hands. The stock had previously closed at $26.16.

Several equities analysts recently commented on the stock. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Leerink Swann reaffirmed a “buy” rating on shares of Genomic Health in a research report on Tuesday, June 21st. Jefferies Group increased their price objective on shares of Genomic Health from $25.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, August 17th. Canaccord Genuity reaffirmed a “buy” rating on shares of Genomic Health in a research report on Thursday, May 5th. Finally, Bank of America Corp. set a $28.00 price objective on shares of Genomic Health and gave the company a “sell” rating in a research report on Wednesday, August 3rd. Three research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $32.44.

The stock’s market cap is $883.00 million. The company has a 50 day moving average price of $27.87 and a 200 day moving average price of $26.57.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.18). The company had revenue of $81.97 million for the quarter, compared to analyst estimates of $81.27 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. The business’s quarterly revenue was up 16.1% compared to the same quarter last year. Equities analysts forecast that Genomic Health Inc. will post ($0.47) earnings per share for the current fiscal year.

In other Genomic Health news, Director Felix Baker bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The stock was purchased at an average price of $27.02 per share, for a total transaction of $2,702,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $26.62, for a total value of $133,100.00. Following the sale, the chief operating officer now owns 40,226 shares of the company’s stock, valued at approximately $1,070,816.12. The disclosure for this sale can be found here.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.